08:00 , Dec 7, 2009 |  BioCentury  |  Finance

Ebb & Flow

The latest follow-on from Human Genome Sciences Inc. (NASDAQ:HGSI) will increase its cash to around $1.1 billion, more than enough to get Benlysta belimumab to market for systemic lupus erythematosus. Indeed, if all goes well,...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Company News

amaxa sales and marketing update

amaxa launched its Nucleofector Kit and two 96-well Shuttle Kits for high throughput DNA and siRNA transfection of mouse dendritic cells. amaxa GmbH , Cologne, Germany   Business: Supply/Service  ...
07:00 , Oct 15, 2007 |  BC Week In Review  |  Company News

amaxa, Promega deal

The companies will combine amaxa's Nucleofactor siRNA transfection technology with Promega's ONE-Glo luciferase assay reagent system to develop applications for monitoring cell-signaling events in stem cells, cancer cells and primary cells. Further terms were not...
07:00 , Jul 24, 2006 |  BC Week In Review  |  Company News

amaxa sales and marketing update

amaxa launched its Nucleofector 96-well Shuttle System for high throughput transfection of primary cells. amaxa GmbH , Cologne, Germany   Business: High throughput screening  ...
07:00 , Jun 12, 2006 |  BC Week In Review  |  Company News

amaxa, Fisher sales and marketing update

The companies will co-promote siRNA libraries from FSH's Dharmacon Inc. subsidiary (Lafayette, Co.) with amaxa's Nucleofector siRNA transfection technology. Further terms were not disclosed. amaxa GmbH , Cologne, Germany   Fisher Scientific International Inc. (FSH),...
07:00 , Oct 3, 2005 |  BC Week In Review  |  Company News

amaxa, American Type Culture Collection deal

American Type will supply amaxa with cell lines. amaxa plans to use the lines to develop and optimize protocols using its Nucleofector non-viral gene transfer technology. amaxa GmbH , Cologne, Germany   American Type Culture...
07:00 , Aug 11, 2003 |  BC Week In Review  |  Company News

amaxa, Qiagen sales and marketing update

The companies will co-market amaxa's non-viral Nucleofector siRNA transfection technology with QIA's HPP (high performance purity) grade siRNA oligonucleotides. amaxa GmbH , Cologne, Germany   Qiagen N.V. (FSE:QIA; QGENF), Venlo, the Netherlands   Business: Supply/Service...
07:00 , Aug 4, 2003 |  BC Extra  |  Financial News

Qiagen beats Street EPS

Qiagen (FSE:QIA; QGENF) reported second quarter EPS of $0.08, beating the Street consensus by a penny and up 60% from $0.05 from the same period last year. Net sales for the quarter came in at...
08:00 , Feb 17, 2003 |  BC Week In Review  |  Company News

amaxa sales and marketing update

amaxa launched its Nucleofector technology for small interfering RNA (siRNA)-induced gene silencing in primary cells and hard-to-transfect cell lines. amaxa GmbH , Cologne, Germany   Business: Gene/Cell therapy  ...
07:00 , Oct 21, 2002 |  BC Week In Review  |  Company News

amaxa genomics news

The company has reduced its headcount to 80 from 100 in a move to reach profitability in 2003. amaxa will now focus on the further development and marketing of its Nucleofector technology for gene transfer...